26 September 2011
Smiths Medical, a division of the global technology business Smiths Group plc, today announced its new Medfusion® 4000 wireless syringe pump and associated software had gained clearance from the U.S. Food and Drug Administration (FDA).
The customizable system, which includes the PharmGuard® software suite, allows health care providers to send and receive medication delivery information more efficiently. Eliminating the need to locate and manually update pumps can significantly help reduce the chance of medication errors.
Smiths Medical President Srini Seshadri said: "This next-generation model of the popular Medfusion® series, which has already been well received in Canada and other countries, demonstrates our ability to develop advanced delivery products that meet a specific clinical demand. Receiving FDA clearance to launch it in the biggest healthcare market in the world is obviously a major breakthrough."
Medfusion® 4000 enables hospitals to capture a wide range of infusion data which PharmGuard® transfers into simple, accessible information for evidence-based practice improvements. As the number of drugs on backorder increases, a wireless system to update drug libraries on pumps improves both patient safety and clinical care by allowing quick and easy updates.
General media enquiries
Contact our global media and communications team at:
Please note – the press team can only answer enquiries from accredited members of the press.
Related articles
Smiths Group’s John Crane business awarded key, global energy transition contracts
Read the latest news from Smiths, as John Crane is awarded key, global energy transition contracts
Find out more
Smiths announces key geothermal win in its John Crane business
Read our latest company news as John Crane marks a significant geothermal win helping accelerate the delivery of clean, reliable power in the United States
Find out more
Smiths celebrates 175 years of engineering excellence
Read our latest company news as Smiths celebrates its 175th anniversary in 2026.
Find out more